Algeta ASA

Algeta is a Norwegian therapeutics company focused on the development of alpha particle emitters as radiopharmaceuticals for the treatment of cancer. The Company is targeting metastatic and disseminated tumor types for which there is substantial unmet medical need. Its first product candidate Alpharadin is targeting skeletal metastases resulting from prostate and breast cancer and is being prepared to enter Phase III clinical trials in hormone refractory prostate cancer.